INTERMEDIATE-RISK GROUP FOR DIFFERENTIATED CARCINOMA OF THYROID

被引:0
作者
SHAHA, AR
LOREE, TR
SHAH, JP
机构
关键词
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. We have previously described prognostic factors in differentiated carcinoma of the thyroid gland relating to age, size and extrathyroid extension of the tumor, histologic grade, gender, and distant metastasis. These factors have identified patients in the low-risk group with excellent prognosis and the high-risk group with significant mortality. However, some patients fall within the intermediate-risk category where due deliberation in decision making is required for selection of appropriate treatment. Methods. A retrospective review of a consecutive series of 1038 previously untreated patients with differentiated carcinoma of thyroid treated during a period of 55 years was undertaken. data gathered from review of the charts were subjected to univariate and multivariate analysis to assess prognostic factors. On the basis of the patient's age, presence of distant metastasis, and size, grade, and histologic characteristics of the tumor they could be classified into low-, intermediate-, and high-risk categories. Thus 403 (39%) patients were in the low-risk group, 232 (22%) patients in the high-risk category, and 403 (39%) patients in the intermediate-risk category. Results. With a median follow-up of 20 years, 99% survival was achieved in the low-risk group, whereas only 57% survived in the high-risk group. Interestingly, in the intermediate-risk category of 403 patients, the 20-year survival was only 85%. Our results clearly identify a distinct intermediate-risk category that includes low-risk patients with high-risk tumor or high-risk patients with low-risk tumor. Conclusion. Patients in the intermediate-risk category should be considered for an aggressive treatment approach based on individual prognostic factors.
引用
收藏
页码:1036 / 1041
页数:6
相关论文
共 50 条
  • [31] Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma
    Marin Prpic
    Ivan Kruljac
    Davor Kust
    Lora S. Kirigin
    Tomislav Jukic
    Nina Dabelic
    Ante Bolanca
    Zvonko Kusic
    Endocrine, 2016, 52 : 602 - 608
  • [32] Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma''
    Schneider, Peter
    Schneider, Rita
    Schneider, Mara
    Reiners, Christoph
    THYROID, 2015, 25 (11) : 1267 - +
  • [33] Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma
    Prpic, Marin
    Kruljac, Ivan
    Kust, Davor
    Kirigin, Lora S.
    Jukic, Tomislav
    Dabelic, Nina
    Bolanca, Ante
    Kusic, Zvonko
    ENDOCRINE, 2016, 52 (03) : 602 - 608
  • [34] ?Micro? Extrathyroidal Extension in Risk Stratification for Papillary Thyroid Carcinoma: Should It Be in the Intermediate-Risk or High-Risk Group? A Single-Center Retrospective Study
    He, Qi
    Ji, Feihong
    Fu, Xinghao
    Li, Zehao
    Qiu, Xinguang
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3181 - 3190
  • [35] FURTHER EVIDENCE OF THE VALIDITY OF RISK GROUP DEFINITION IN DIFFERENTIATED THYROID-CARCINOMA
    CADY, B
    ROSSI, R
    SILVERMAN, M
    WOOL, M
    SURGERY, 1985, 98 (06) : 1171 - 1178
  • [36] AN EXPANDED VIEW OF RISK-GROUP DEFINITION IN DIFFERENTIATED THYROID-CARCINOMA
    CADY, B
    ROSSI, R
    SURGERY, 1988, 104 (06) : 947 - 953
  • [37] A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer
    Arash Abiri
    Theodore Nguyen
    Khodayar Goshtasbi
    Sina J. Torabi
    Edward C. Kuan
    William B. Armstrong
    Tjoson Tjoa
    Yarah M. Haidar
    European Archives of Oto-Rhino-Laryngology, 2023, 280 : 2525 - 2533
  • [38] Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
    Danilovic, Debora L. S.
    Coura-Filho, George B.
    Recchia, Giulianna M.
    Castroneves, Luciana A.
    Marui, Suemi
    Buchpiguel, Carlos A.
    Hoff, Ana O.
    Kopp, Peter
    ENDOCRINE-RELATED CANCER, 2022, 29 (08) : 475 - 483
  • [39] Development of prognostic signatures for intermediate-risk papillary thyroid cancer
    Brennan, Kevin
    Holsinger, Christopher
    Dosiou, Chrysoula
    Sunwoo, John B.
    Akatsu, Haruko
    Haile, Robert
    Gevaert, Olivier
    BMC CANCER, 2016, 16
  • [40] Development of prognostic signatures for intermediate-risk papillary thyroid cancer
    Kevin Brennan
    Christopher Holsinger
    Chrysoula Dosiou
    John B. Sunwoo
    Haruko Akatsu
    Robert Haile
    Olivier Gevaert
    BMC Cancer, 16